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RNA sequencing analysis of human 
podocytes reveals glucocorticoid 
regulated gene networks targeting 
non-immune pathways
Lulu Jiang1, Charles C. T. Hindmarch2,3, Mark Rogers4, Colin Campbell4, Christy Waterfall5, 
Jane Coghill5, Peter W. Mathieson6 & Gavin I. Welsh1
Glucocorticoids are steroids that reduce inflammation and are used as immunosuppressive drugs for 
many diseases. They are also the mainstay for the treatment of minimal change nephropathy (MCN), 
which is characterised by an absence of inflammation. Their mechanisms of action remain elusive. 
Evidence suggests that immunomodulatory drugs can directly act on glomerular epithelial cells or 
‘podocytes’, the cell type which is the main target of injury in MCN. To understand the nature of 
glucocorticoid effects on non-immune cell functions, we generated RNA sequencing data from human 
podocyte cell lines and identified the genes that are significantly regulated in dexamethasone-treated 
podocytes compared to vehicle-treated cells. The upregulated genes are of functional relevance to 
cytoskeleton-related processes, whereas the downregulated genes mostly encode pro-inflammatory 
cytokines and growth factors. We observed a tendency for dexamethasone-upregulated genes to be 
downregulated in MCN patients. Integrative analysis revealed gene networks composed of critical 
signaling pathways that are likely targeted by dexamethasone in podocytes.
Glucocorticoids (GCs) are a class of steroid hormones used as frontline immunomodulatory drugs in the treat-
ment of many inflammatory diseases owing to their potent effects on immune cells. However, GCs are also ther-
apeutically effective in Minimal Change Nephropathy (MCN) which is characterised by a lack of inflammation 
in the kidney. This raises the question as to how GCs exert their therapeutic efficacy on non-immune cells such 
as those in the kidney.
MCN is the most common cause of nephrotic syndrome in children, accounting for approximately 80% of 
cases. Patients with MCN suffer from massive leakage of protein from the blood stream into the urine, resulting 
from dysfunction of the glomerular filtration barrier (GFB) of the kidney. The GFB functions as a blood filter, pre-
venting protein loss into urine (Fig. 1A). It is mainly composed of two cell types: glomerular endothelial cells and 
glomerular epithelial cells (or ‘podocytes’), separated by a specialized glomerular basement membrane (GBM).
Increasing evidence points to the importance of podocytes in glomerular disease. Mutations in 
podocyte-specific genes1–4 cause congenital or early-onset nephrotic syndrome. Proteins encoded by many of 
these genes reside in the slit diaphragm - a structure connecting adjacent podocyte foot processes. They interact 
with other proteins to regulate the podocyte actin cytoskeleton which underlies the function of these cells and 
the glomerulus5,6. In addition to their importance in glomerular function, we and others have also shown that 
podocytes are a promising cellular target for immunomodulatory drugs in the treatment of glomerular diseases. 
In 2008, PW Mathieson7 proposed that drug therapies for glomerular diseases may exert some or all of their 
therapeutic effects via direct actions on the glomerular podocytes rather than via the modulation of immune cell 
function. Since then numerous studies have demonstrated that these drugs do act directly on podocytes8–10, and 
that their efficacy in treating proteinuria can be independent of their effects on immune cells11.
1Bristol Renal, School of Clinical Sciences, University of Bristol, Bristol, UK. 2Department of Biomedical and Molecular 
Sciences, Queen’s University, Kingston, ON, Canada. 3Department of Physiology, Faculty of Medicine, University 
of Malaya, Kuala Lumpur, Malaysia. 4Department of Engineering Mathematics, University of Bristol, Bristol, UK. 
5Bristol Genomics Facility, School of Biological Sciences, University of Bristol, Bristol, UK. 6President’s Office, The 
University of Hong Kong, Hong Kong, China. Correspondence and requests for materials should be addressed to 
G.I.W. (email: g.i.welsh@bristol.ac.uk)
Received: 06 June 2016
accepted: 29 September 2016
Published: 24 October 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:35671 | DOI: 10.1038/srep35671
The underlying molecular mechanisms as to how GCs exert their therapeutic effects on podocytes are still 
unclear. To address this, we utilised our established conditionally immortalized human podocyte cell lines for 
RNA sequencing (RNA-seq) to generate a genome-wide expression profile of the effects of dexamethasone on 
human podocytes derived from three different healthy kidney donors. We further demonstrate the usefulness of 
this resource in revealing transcriptome features that may explain the efficacy of glucocorticoids in disease. In a 
wider context, our results advance the knowledge of glucocorticoids targeting non-immune cell functions.
Results and Discussion
RNA sequencing analysis of podocytes treated with dexamethasone. We have used 3 human 
podocyte cell lines for sequencing which were derived from the kidneys of 3 independent healthy donors. Based 
on three biological replicates in a paired design (Fig. 1A), we identified 2,276 genes in podocytes that were signif-
icantly regulated upon dexamethasone treatment. These genes were then analysed using a supra-hexagonal map 
for gene clustering and visualization. Cell line-specific transcriptome changes are illustrated in Fig. 1B, in which 
genes with similar patterns across cell lines are mapped onto the same regions in the map. Comparison of these 
illustrations demonstrates a considerable consistency of expression changes across the cell lines. To better reveal 
inherent relations between these genes, we applied a topology-preserving clustering procedure identifying seven 
gene meta-clusters (Fig. 1C): highly downregulated (cluster 1), downregulated (clusters 2–4), highly upregu-
lated (cluster 5), and upregulated (clusters 6–7). Genes within each of the seven clusters displayed highly similar 
expression patterns in all cell lines, suggesting that they share common features. Detailed information about these 
genes and their cluster memberships can be found in Supplementary Table 1.
Enrichment analysis reveals functional characteristics of dexamethasone–treated podo-
cytes. To reveal the functional relevance of dexamethasone-regulated genes in podocytes, we next performed 
enrichment analysis of genes in each of the 7 clusters using Gene Ontology (GO), BioCarta, KEGG and Reactome 
pathways, and transcription factor binding sites (TFBSs). The GO terms, pathways and TFBSs that were signif-
icantly associated with the gene clusters are illustrated in Fig. 2, and the functional characteristics identified are 
summarized below.
Dexamethasone-downregulated genes are largely pro-inflammatory cytokines and growth factors. Intriguingly, 
we found that genes repressed in cluster 1–4 by dexamethasone included a wide variety of genes encoding 
Figure 1. RNA sequencing analysis of 3 podocyte cell lines derived from independent healthy donors. 
(A) Experimental design. Conditionally immortalized human podocytes were developed from 3 kidney 
transplant donors. Differentiated cells were treated with PBS or 0.1 μ M dexamethasone for 24 hours, which 
were then subjected to RNA extraction and sequencing. On the top right illustrates the structural composition 
of glomerular filtration barrier and the occurrence of protein loss into urine in disease. Notation: Con, control; 
Dex, dexamethasone; GBM, glomerular basement membrane; CL1-3, cell lines 1–3. (B) Cell line-specific 
transcriptome changes in response to dexamethasone. Clustering and visualization of differentially expressed 
genes were analysed using a supra-hexagonal map. Genes with similar patterns across cell lines are mapped onto 
the same or nearby regions in the map. (C) A map illustrating 7 gene meta-clusters.
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pro-inflammatory cytokines including chemokines (CCL2, CXCL12), interleukins (IL11, IL6, IL23A), TNF, 
TGFB1, CSF2, and some interferon regulatory factors (IRF2, IRF6). Fibroblast growth factors (FGF2, FGF5) 
and vascular endothelial growth factors (VEGFA, VEGFC) were also suppressed. We have previously reported 
that dexamethasone downregulates VEGF in podocytes12, thus here VEGF genes serve as an internal control for 
our sequencing data. Furthermore, as shown in Fig. 2, the GO pathways observed in cluster 1–4 included the 
JNK cascade and inflammatory responses that are the classic pathways by which GCs universally exert suppres-
sive effects. The transcription factors enriched from the TFBSs analysis are diverse and include NFκ B and AP1 
(Supplementary Table 2), crucial transcriptional regulators of pro-inflammatory genes, which are known to be 
the transrepression targets of the glucocorticoid receptor (GR) for its anti-inflammatory effects13. Interestingly, 
podocytes appear to be capable of expressing and producing cytokines such as IL-1 and CXCL1214,15 and upregu-
lating the NFκ B cascade signaling during injury16 which could consequently contribute to glomerular injury17. In 
this case, repression of cytokine genes and related pathways in podocytes might represent part of the mechanism 
by which glucocorticoids exert benefits in certain glomerular diseases such as MCN.
Dexamethasone-upregulated genes are linked to cytoskeleton-related process. Genes in cluster 5–7 are related to 
the structure of the podocyte. A large number of these genes encode actin binding proteins (MYO1C, MYO9A), 
structural constituents of the cytoskeleton (MSN, TUBB, TUBA1B), and actin regulatory proteins (INF2, ROCK1, 
PPP1CB, PPP2CB) (Table 1). Podocytes contain microtubules and intermediate filaments in their cell bodies 
and major processes for structural support for the cell, and microfilaments in the foot processes forming the 
highly delicate cytoskeletal architecture that underlies the function of the cell. A common pathological feature 
of nephrotic syndrome is podocyte foot process effacement. When the cytoskeleton network in podocytes is dis-
rupted, the cells become flat and more motile, leading to proteinuria. Thus, maintaining the podocyte cytoskele-
ton is crucial for normal functioning glomerular filters18. Interestingly, both microtubule (α -and β -tubulin) and 
microfilament (α -actinin and myosin) encoding genes were found to be upregulated by dexamethasone (Table 1). 
In addition, KIF23, encoding CHO1/MKLP1, a kinesin-like protein that is essential for process formation19, and 
MAP4, encoding microtubule-associated protein which promotes microtubule assembly and stabilization20 were 
also induced. PPP2CB encodes phosphatase 2A (PP2A) catalytic subunit. Interestingly, in podocyte expres-
sion of this protein appears to be developmentally regulated21: in vivo, only process-forming cells express high 
level of PP2A22,23. Inhibition of PP2A in cultured podocytes abolishes process formation and causes abnormal 
microtubule assembly24. Therefore, upregulation of PP2A by dexamethasone could promote podocyte process 
Figure 2. Enrichment analysis of the clustered genes. Functional enrichment analysis for genes in each of 
the 7 clusters is based on Gene Ontology molecular function (GOMF) and biological process (GOBP). KEGG, 
BioCarta and Reactome pathways are used for pathway enrichment analysis, and transcription factor binding 
sites (TFBSs) for TF enrichment analysis. Notation: CL1–3, cell lines 1–3.
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formation and potentially attenuate podocyte injury during disease. EZR (encoding protein Ezrin) is another 
important gene induced by dexamethasone. Ezrin is an actin-binding protein that connects plasma membrane 
and actin cytoskeleton as an intermediator, and has been reported to be downregulated in diabetic glomeruli25. 
Furthermore, the transcription factor SRF (serum response factor) was found to be significantly enriched in 
cluster 5 and 6. SRF is reported to be a master regulator of actin cytoskeleton26 which can be activated by RhoA 
during filamentous actin (F-actin) polymerization27,28. A low level of RhoA causes the loss of podocyte stress 
fibers and is associated with foot process effacement29 which is a typical feature of MCN30. A large number of 
SRF-targeted genes were upregulated by dexamethasone, implicating the important role it may play in the actin 
regulation in podocytes. Our observations on the dramatic effects of dexamethasone on podocyte actin related 
genes are consistent with previous studies31–33 showing that dexamethasone protects and stabilizes podocyte actin 
cytoskeleton. Taken together, our data suggest that effects of dexamethasone on the podocyte cytoskeleton may 
involve the regulation of both microtubules and actin filaments, which could maximally promote the stability of 
the cell structure and function.
Dexamethasone regulates genes that are involved in podocyte differentiation. Of note, dexamethasone has been 
reported to restore the podocyte differentiation markers and ameliorate podocyte injury in proteinuric murine 
models34. Podocyte-specific transcription factor Wilm’s Tumor protein 1 (WT1) plays crucial role in glomerular 
differentiation and podocyte function35,36. At the early stage of podocyte differentiation, the expression of WT1 
is highest37. AREG (amphiregulin) is a known target gene of WT1 and it enhances branching morphogenesis of 
ureteric bud during kidney differentiation38,39. Of interest, we noted that AREG was significantly upregulated by 
dexamethasone (Supplementary Table 1). Similarly, there was also an upregulation in FOXC2 (Supplementary 
Table 1), a transcription factor known to be involved in the podocyte specification40 and which cooperates with 
FOXC1 to maintain podocyte function41. Combined knockdown of WT1 and FOXC2 resulted in a loss of all 
podocyte marker gene expression42. This data may suggest the importance of these genes in promoting podocyte 
differentiation and cell function by dexamethasone.
Comparative analysis identifies therapeutic candidate targets for MCN. Dexamethasone-regulated 
genes represent a wide transcriptional spectrum characteristic of podocytes responding to glucocorticoids. To 
identify therapeutic candidate targets from this wide spectrum of genes, we further conducted a comparative 
analysis relative to the publically available transcriptome data of MCN patients. According to the Nephroseq 
database, we defined two MCN-specific gene signatures: a downregulated signature and an upregulated signature 
(Supplementary Table 3). Using GSEA we found that genes in the MCN-downregulated signature had a signifi-
cant tendency of being upregulated by dexamethasone (Fig. 3A,B), whereas no such tendency was observed for 
genes in the MCN-upregulated signature. This implies that dexamethasone is able to reactivate gene expression 
programs that are suppressed in the disease state. Based on this finding, we identified 9 therapeutic candidate 
target genes that are repressed in MCN but are induced by dexamethasone (Fig. 3C).
Candidate genes that are associated with glucocorticoids’ immune-efficacy. Notably, among the 9 candidate genes, 
three genes (FKBP5, TSC22D3 and DUSP1) are well-known glucocorticoid-induced genes that are involved in the 
immunosuppressive actions of glucocorticoids, but their roles in podocyte and glomerular function are unclear. 
FKBP5 (FK506 binding protein 51) is an hsp90 co-chaperone protein that is bound to GR and regulates GR sensi-
tivity43. TSC22D3 (also known as GILZ, glucocorticoid-induced leucine zipper) inhibits the transcriptional activ-
ity of its target proteins such as NFκ B44 and reduces the expression of costimulatory molecules CD80 and CD86 in 
macrophages and their production of chemokines45. In addition to mediating the anti-inflammatory effects, GILZ 
has also been reported to be involved in the regulation of T-helper cell differentiation46 and the increase of the 
epithelial Na+ transport in the kidney47. DUSP1 (dual specificity phosphatase 1) is a mitogen-activated protein 
kinase (MAPK) phosphatase that plays a partial role in dexamethasone-dependent repression of inflammatory 
genes48. DUSP1−/− mice show high sensitivity to lipopolysaccharides (LPS) and exhibit significantly increased 
serum cytokine levels48. However the mechanisms by which these glucocorticoid-targeted genes play a role in the 
dysfunction of podocytes in MCN need to be established.
Cluster Molecular Function P-value FDR Gene Name
5 actin binding 0.0011 0.015 KLHL4, SHROOM2, DIAPH2, FSCN1, SNTA1, TAGLN, TPM2, HOMER2, DSTN,DIXDC1, FGD4, GAS2L3
6 actin binding 2.5E-12 9.60E-11
MSN, MYO1C, MYO9A, CALD1, CAPG,CFL1, CNN2, DIAPH1, 
EMD, FLNB, ABLIM1, OPHN1, PLEC, PLS3, TLN1, TPM4
VASP, VCL, WIPF1, WDR1, ARPC1B, ACTR2, CAP1, PDLIM5, 
GIPC1, PALLD, SPTBN5, SSH3, PARVA, MTSS1L, SYNPO2
6 structural constituent of cytoskeleton 0.00002 0.00025
MSN, TUBA1B, TUBB4B, TLN1, ARPC1B, TUBB, TUBB2B, 
ACTG1, NEFL, SORBS3
7 microtubule binding 0.000031 0.00035 MAST2, CENPE, KIF23, KIF13B, KIFC2, KIF24, RACGAP1, MAP4, MAP6D1, PRC1, SBDS, KATNAL1
7 actin binding 0.001 0.0049 DAG1, TPM3, ADD1, CFL2, EPS8, UTRN, YWHAH, ARPC5, EPB41L3, RUSC1, TMOD3, ANLN,INF2, CLMN, DIAPH3
Table 1.  Actin/microtubule-related genes upregulated by dexamethasone.
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Candidate genes that are actin-related but novel in relation to podocytes. It is worth noting that 2 of the 9 can-
didate genes are actin-related genes (NEDD9 and ADD1). NEDD9, also known as enhancer of filamentation 
1 (EF1), localizes to49 and stabilizes focal adhesions and increases binding of the cell to extra cellular matrix 
(ECM)50. The absence of NEDD9 leads to an increased rate of focal adhesion disassembly and decreased adhesion 
to fibronectin in mouse embryo fibroblasts. β 1 integrin activation is also significantly suppressed in NEDD9−/− 
cells50. However the role of NEDD9 in regulating focal adhesion in podocytes has not been reported. ADD1 
(Adducin 1) is an actin-binding protein that is important for stabilization of the membrane cortical cytoskel-
eton51,52 and cell-cell adhesion53,54. It was also reported to associate with mitotic spindles and interact with 
Myosin-X to regulate spindle assembly and mitotic progression55. Upregulation of ADD1 and NEDD9 in podo-
cytes may suggest that dexamethasone is able to restabilize the actin skeleton by increasing the expression of actin 
components which are lost in disease, and may also strengthen the weakened binding to the ECM by mediating 
focal adhesions reestablishing the signaling transduction between the ECM and the actin cytoskeleton.
Candidate genes identified from transcriptome comparative analysis were further validated. Figure 3D shows 
the induced-expression of candidate genes by dexamethasone in podocytes validated by real-time RT-PCR 
(Upregulation of FKBP5 and DUSP1 has been reported in our previous study8 so they were excluded from vali-
dation here). In summary, these genes were identified to be repressed in MCN but activated by dexamethasone, 
suggesting that they play an important role in glomerular function, and may represent potential novel therapeutic 
targets.
Integrative analysis identifies gene networks of dexamethasone targeting podocytes. It is 
likely that genes regulated by dexamethasone do not function alone but instead work together as a network. 
To identify such an interconnected-gene network we carried out integrative analysis through integration of 
Figure 3. Comparative analysis of RNA-seq data with the transcriptome data of MCN patients. (A,B) GSEA 
shows that genes in the MCN-downregulated signature had a tendency of being significantly upregulated by 
dexamethasone, whereas no such tendency was observed for genes in the MCN-upregulated signature. (C) The list 
of 9 therapeutic candidate target genes identified as being repressed in MCN but upregulated by dexamethasone. 
(D) Real-time RT-PCR validation of the identified potential therapeutic targets. Cells were treated with vehicle 
or dexamethasone (0.1 μ M) for 24 hours and then RNA was extracted and analyzed by real-time RT-PCR. Values 
were normalized to GAPDH and fold changes compared with vehicles were plotted as means ± SE from triplicates 
of four independent experiments. Dotted line indicates the basal expression. Notation: dexamethasone treatment 
versus vehicle (*); Significance: **P < 0.01, ***P < 0.001.
www.nature.com/scientificreports/
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our RNA-seq expression data with known protein interaction data. As a result, two networks were identified, 
one for downregulated genes and the other for upregulated genes. The downregulated-gene network signifies 
a broad-spectrum of effects of glucocorticoids on cell proliferation, survival, and immune-related process (see 
Supplementary Fig. 1 and Supplementary Table 4). The upregulated-gene network depicts a podocyte-specific 
interconnection between RAS/MAPK signaling, regulation of actin cytoskeleton and focal adhesion, and calcium 
signaling. These interactions are well captured by the community structure (communities C1–C4) (Fig. 4 and 
Table 2), demonstrating the key signaling network that dexamethasone positively regulates in podocytes.
Gene network negatively regulated by dexamethasone reveals the association of P53 signalling with cytokine and 
growth factor pathways in podocytes. The crosstalk between TP53 (P53) signaling pathway (C1), cytokine sig-
naling (C2) and growth factor signaling (C3) were observed in the gene network downregulated by dexameth-
asone. The hub genes of respective communities mediate this crosstalk: P53 in C1, IL6 in C2 and VEGFA in C3. 
As shown in the Supplementary Fig. 1, C3 was tightly linked to C2 via direct interactions of VEGFA with mul-
tiple genes including MMP2, IGFBP3, TNF, HMOX1, CXCL12 and TGFB1. GR activated by dexamethasone is 
reported to inhibit P53-induced cell cycle arrest and apoptosis by interacting with P53 and subsequently leading 
to inactivation of P53 via cytoplasmic sequestration56. The crosstalk between the P53 pathway and cytokine and 
growth factor signaling suggests that dexamethasone affects podocyte proliferation and survival by negatively 
regulating P53, and this negative regulation may also be associated with its repressive effects on cytokine and 
growth factor-related genes.
Gene network upregulated by dexamethasone illustrates podocyte-specific crosstalk of signaling pathways in response 
to glucocorticoid. As seen in Fig. 4, we found that the EGFR gene in the community of integrin binding and 
ECM organization (C3) directly connected to two other communities: the RAS/MAPK signaling pathway com-
munity (C1) and the calcium signaling community (C4), and indirectly linked to the actin regulation community 
(C2) via the DCN gene. The identification of EGFR as a hub gene is reasonable: integrin-mediated cell adhesion 
to ECM proteins induces partial activation of EGFR in epithelial cells, and this activation is required for multiple 
Figure 4. Gene network upregulated by dexamethasone in podocytes. The network is identified through 
integrative analysis of our RNA-seq expression data with known protein interaction data. Four communities 
were identified (C1–C4). Enrichment analysis shows the crosstalk of RAS/MAPK signalling, regulation of actin 
cytoskeleton and focal adhesion, and calcium signalling in this gene network.
www.nature.com/scientificreports/
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Name Description Log2(FC) P-value FDR
C1:RAS/MAPK signalling
 DUSP1 dual specificity phosphatase 1 0.89 2.9E-31 7.3E-29
 TSC22D3 TSC22 domain family, member 3 1.57 4.7E-31 1.1E-28
 CCND3 cyclin D3 0.87 2.0E-26 3.7E-24
 EFNB2 ephrin-B2 0.78 7.8E-23 1.1E-20
 SGK1 serum/glucocorticoid regulated kinase 1 1.15 1.9E-22 2.5E-20
 ZFP36 ZFP36 ring finger protein 0.88 6.1E-19 6.2E-17
 KRT8 keratin 8 0.91 1.8E-12 9.3E-11
 SMYD2 SET and MYND domain containing 2 0.42 1.9E-10 7.4E-09
 ITSN1 intersectin 1 (SH3 domain protein) 0.37 1.1E-08 3.3E-07
 CAPN2 calpain 2, (m/II) large subunit 0.49 1.5E-06 3.0E-05
 RRAS related RAS viral (r-ras) oncogene homolog 0.32 4.7E-06 8.4E-05
 RB1 retinoblastoma 1 0.24 4.9E-04 4.9E-03
 RAF1 v-raf-1 murine leukemia viral oncogene homolog 1 0.19 3.3E-03 2.4E-02
 MAPK1 mitogen-activated protein kinase 1 0.20 4.1E-03 2.9E-02
C2:Actin cytoskeleton regulation
 TGFBR1 transforming growth factor, beta receptor 1 1.30 6.3E-42 2.9E-39
 CHRD chordin 1.18 3.6E-37 1.3E-34
 SERPINE1 serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1 1.58 6.7E-35 2.2E-32
 PER1 period circadian clock 1 1.52 9.7E-34 2.7E-31
 CTTNBP2 cortactin binding protein 2 0.73 4.0E-14 2.5E-12
 CHRDL1 chordin-like 1 0.55 1.7E-11 7.8E-10
 TGFB2 transforming growth factor, beta 2 0.47 1.4E-09 4.7E-08
 NPAS2 neuronal PAS domain protein 2 0.56 6.4E-09 2.0E-07
 VASP vasodilator-stimulated phosphoprotein 0.40 3.9E-08 1.0E-06
 TGFBR2 transforming growth factor, beta receptor II (70/80kDa) 0.38 4.8E-08 1.3E-06
 LPP LIM domain containing preferred translocation partner in lipoma 0.37 1.6E-07 3.8E-06
 MYL9 myosin, light chain 9, regulatory 0.57 1.9E-07 4.4E-06
 PPP1CB protein phosphatase 1, catalytic subunit, beta isozyme 0.36 3.3E-07 7.5E-06
 ACTN1 actinin, alpha 1 0.54 8.2E-07 1.7E-05
 PPP2CB protein phosphatase 2, catalytic subunit, beta isozyme 0.34 2.7E-06 5.1E-05
 BAMBI BMP and activin membrane-bound inhibitor 0.41 2.7E-06 5.1E-05
C3:Integrin binding and extracellular matrix organization
 DCN decorin 1.59 2.4E-65 3.6E-62
 IRS2 insulin receptor substrate 2 1.51 4.0E-52 3.0E-49
 COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) 1.09 1.5E-18 1.5E-16
 PTPN1 protein tyrosine phosphatase, non-receptor type 1 0.63 1.1E-15 7.9E-14
 COL4A4 collagen, type IV, alpha 4 0.89 4.4E-14 2.7E-12
 TERT telomerase reverse transcriptase 0.75 3.2E-09 1.0E-07
 LUM lumican 0.48 4.9E-09 1.5E-07
 COL8A1 collagen, type VIII, alpha 1 0.69 2.7E-08 7.4E-07
 PTPRJ protein tyrosine phosphatase, receptor type, J 0.43 2.9E-08 7.9E-07
 PDGFB platelet-derived growth factor beta polypeptide 0.37 1.7E-07 4.1E-06
 EPS8 epidermal growth factor receptor pathway substrate 8 0.37 5.8E-07 1.3E-05
 RUVBL2 RuvB-like AAA ATPase 2 0.31 1.4E-06 2.7E-05
 BTC betacellulin 0.53 5.7E-06 9.9E-05
 COL5A1 collagen, type V, alpha 1 0.33 1.3E-04 1.5E-03
 SDC3 syndecan 3 0.28 1.9E-04 2.2E-03
 EGFR epidermal growth factor receptor 0.23 3.6E-03 2.6E-02
C4:Calcium signalling
 SNTA1 syntrophin, alpha 1 0.67 3.0E-15 2.0E-13
 DGKI diacylglycerol kinase, iota 0.55 3.6E-14 2.2E-12
 EDN1 endothelin 1 0.67 2.4E-13 1.4E-11
 S100A10 S100 calcium binding protein A10 0.58 1.2E-11 5.8E-10
Continued
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signal transduction events including the activation of Ras/Erk signaling57,58. TGFB1 expression was suppressed 
by dexamethasone, however TGGBR1, TGFBR2 and TGFB2 were upregulated in C2, and TGFB2 appeared to be a 
link for actin-related genes to connect to RAS/MAPK pathway via RB1 and to integrin signaling pathway via the 
gene DCN. In addition, EGFR links SDC3 (encoding syndecan 3, an adhesion receptor) and SDC3 then connects 
to several collagen-encoding genes COL5A1, COL4A3, COL4A4 and COL8A1. GBM (illustrated in Fig. 1A) is a 
dense network of ECM containing collagen IV and laminin and other structural and regulatory proteins59. The 
absence of the collagen IV α 3α 4α 5 can cause Alport syndrome and progressive renal failure60,61. Interestingly 
dexamethasone upregulated COL4A3 (collagen IV α 3) and COL4A4 (collagen IV α 4) and also repressed the 
expression of some other collagen genes such as COL6A3, COL14A1 and COL27A1. Notably, EGFR also links 
to C4 via CALM1 (encoding calmodulin 1) indicating the important involvement of calcium signaling in the 
regulation of podocyte function by dexamethasone. Indeed, Ca2+ signaling is very important: the shape of each 
cell is regulated by Ca2+/calmodulin through controlling the interactions of myosin with cytoskeletal actin62,63.
Taken together, these two networks clearly illustrate the coordinated cellular response to dexamethasone treat-
ment in podocytes. P53 may play an important role in mediating glucocorticoid-dependent effects on podocyte 
proliferation, survival and cytokine regulation. Integrin signaling exhibits as a central regulator that leads the 
crosstalk between RAS/MAPK signaling, regulation of actin, and calcium signaling, suggesting it is an important 
target for glucocorticoid action in podocytes. Importantly, DUSP1 and GILZ, the genes repressed in disease, were 
found in the upregulated gene network, which raise the possibility of their functional connection with actin reg-
ulation and integrin signaling pathways.
Conclusions
We are the first to apply RNA-seq in generating transcriptome data that is informative for understanding molec-
ular mechanisms of GCs’ effectiveness in non-inflammatory glomerular disease. Our data illustrates that the 
effects of dexamethasone on podocytes in general function in two ways: 1) suppression of the cells’ capacity to 
produce pro-inflammatory mediators in response to injury to limit/prevent the damage to the glomerulus, and 2) 
enhancement of podocyte intrinsic function by promoting the stabilization of the actin cytoskeleton and its bind-
ing to GBM. In terms of MCN, the latter could be the main mechanism. These findings will advance our under-
standing of the efficacy of GCs in nephrotic syndrome. New candidate targets identified in this study will facilitate 
the development of novel podocyte-targeted treatment without causing systemic toxicity.
Methods
Podocyte culture and glucocorticoid treatment. All experimental protocols were approved by the 
NRES Committee South West-Central Bristol and were performed in accordance with Committee guidelines. 
Conditionally immortalized human podocytes were established from three kidney transplant donors with no 
kidney disease64. Cell lines were regularly tested and were mycoplasma-free. Cells were grown to 70–80% con-
fluence at 33 °C in 5% CO2 before thermo-switching to 37 °C in 5% CO2 and allowed to differentiate for 10 days. 
Differentiated cells were then treated with PBS (vehicle) or 0.1μ M dexamethasone (Sigma–Aldrich) for 24 hours, 
then subsequently used for RNA extraction and sequencing.
RNA extraction, cDNA library construction and sequencing. Total RNA was extracted from control 
and dexamethasone-treated podocytes using the TRIzol method. RNA samples were then subjected to DNase 
treatment (Ambion TURBO DNase, Life Technologies) and purification (RNeasy Mini Kit, QIAGEN) according 
to the manufacturer’s instructions. The cDNA library preparation and the sequencing were performed following 
manufacturer’s instructions at the Bristol Genomics Facility, University of Bristol. Briefly, approximately 1μ g of 
purified total RNA was prepared for sequencing using the Illumina TruSeq mRNA Seq v2 kit. Sequencing of 
100bp paired-end reads was performed with the Illumina HiSeq 2500 instrument. The raw data was processed 
using Illumina software, RTA 1.17.21.3 with default filter and quality settings. The reads were demultiplexed 
(allowing no mismatches in the index sequence) with CASAVA 1.8.2.
RNA-seq data mining. RNA-seq alignment and analysis was performed in house using our 
high-performance computer, ‘Hydra’. We use a pipeline that accepts RNA-seq data as input and produces tables 
of predictions for differentially expressed genes. Read alignment is performed using Tophat65. We use HTSeq66 to 
generate read counts, using the ENSEMBL GRCh37 annotations for reference. In order to determine those genes 
that are differentially expressed (DE), our pipeline makes use of three methods from the R Bioconductor package: 
DESeq67, edgeR68 and baySeq69. DESeq and edgeR are both competitive with the state of the art, while baySeq 
yields high precision in cases where there is no expression evident in one sample but weak or moderate expression 
in another sample70. The DE predictions from DESeq and edgeR allow us to establish high-confidence predictions 
Name Description Log2(FC) P-value FDR
 ITPK1 inositol-tetrakisphosphate 1-kinase 0.41 8.5E-10 3.0E-08
 ITPKA inositol-trisphosphate 3-kinase A 0.81 8.0E-09 2.4E-07
 EDN2 endothelin 2 1.01 1.2E-08 3.4E-07
 ANXA2 annexin A2 0.46 8.2E-08 2.1E-06
 CALM1 calmodulin 1 (phosphorylase kinase, delta) 0.38 6.8E-07 1.4E-05
 PLCB3 phospholipase C, beta 3 (phosphatidylinositol-specific) 0.31 1.1E-06 2.2E-05
Table 2.  List of genes in network communities upregulated by dexamethasone.
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that have low p-values from both methods. Data was organised using a spreadsheet and is filtered according to 
the edgeR adjusted p-value with a 0.05 cut-off applied. A total of 2,276 genes were identified as differentially 
expressed genes between the dexamethasone group and the control group taking into account the paired design 
across the 3 cell lines, and used for further analysis. For gene clustering and visualization, the gene expression 
matrix was analyzed by the supraHex package71. Genes with similar expression changes were self-organised onto 
nearby regions of a supra-hexagonal map. The resulting map was visualized to display sample-specific expression 
changes, and was also further partitioned to obtain 7 gene meta-clusters. For each meta-cluster, enrichment anal-
ysis was conducted using the function dEnricher in the dnet package72 to identify enriched functions (represented 
as Gene Ontology terms), enriched pathways (from BioCarta, KEGG and Reactome), and enriched transcription 
factor binding sites (TFBS).
Comparisons with publicly available transcriptome data of MCN patients. Comparisons of differ-
entially expressed genes against the MCN patient transcriptome data were carried out using the gene set enrich-
ment analysis (GSEA) algorithm. In brief, MCN-specific gene signatures were first defined based on the MCN 
patient transcriptome data (obtained from the Nephroseq database ‘Ju Podocyte’; https://www.nephroseq.org). 
Differentially expressed genes were pre-ordered from the highest upregulations to the highest downregulations. 
Then, the function dGSEA in the dnet package was applied to determine the tendency of genes in a MCN-specific 
gene signature to be at the top or bottom of a pre-ordered differentially expressed genes. This tendency was quan-
tified by running enrichment score, and the enrichment significance by p-value.
Identification of the gene network in dexamethasone-treated podocytes. The dnet package was 
used to identify the gene network that contains groups of interconnected genes. Genes from the identified net-
work are mostly significantly regulated in dexamethasone-treated podocytes but also contain a few less signif-
icant genes as linkers. Specifically, the dNetPipeline function in the package took as inputs a list of differentially 
expressed genes with the significance level (e.g. FDR), projected these genes onto the human protein association 
data from the STRING database (highest confidence > 900)73, and output a 56-gene network (under the tolerable 
thresholds of FDR < 1E-4). For a better visualization of the gene network structure, communities in the network 
were also detected via a span-glass model and simulated annealing.
Real-time reverse transcription (RT)-PCR analysis. RNA extracted from cells using TRIzol 
(Invitrogen) method according to manufacturer’s instructions. High capacity RNA to cDNA kit (Applied 
Biosystems) was used to make cDNA as per the manufacturer’s instructions. Real-time PCR using SYBR Green 
(Sigma) was performed using StepOnePlus Real-Time PCR System (Applied Biosystem) and StepOne Software 
v2.1. Data was analyzed using Δ Δ Ct method. Primer sequences used are listed below:
 GAPDH forward primer 5′ -TGATGACATCAAGAAGGTGG-3′ , reverse primer 5′ -TTTCTTA 
CTCCTTGGAGGCC-3′ ;
 GILZ forward primer 5′ -GATGTGGTTTCCGTTAAGC-3′ , reverse primer 5′ - CTCTCTCACAGCATACA 
TCAG-3′ ;
 GADD45B forward primer 5′ -ATGAATGTGGACCCAGACAGC-3′ , reverse primer 5′ -GCGTGAAGT 
GGATTTGCAGG-3′ ;
 TMEM2 forward primer 5′ -GCACGGGGTTACTGTTTTTGT-3′ , reverse primer 5′ -GAGTCTG 
TGGCTGCTTGGAT-3′ ;
 GLUL forward primer 5′ -CCAAGTGTGTGGAAGAGTTGC-3′ , reverse primer 5′ -GCAGCAGGCA 
CGAGATACAT-3′ ;
 NEDD9 forward primer 5′-GGGACCTTCTCGCTTTCATCT-3′, reverse primer 5′-GTGGGTTGAG 
CCGTTTTCCT-3′ ;
 ZEB1 forward primer 5′-TCATTGTGGAGAGATGACTTGT-3′ , reverse primer 5′-AGCGGCAACAGC 
TCAATATG-3′ ;
 ADD1 forward primer 5′ -GGGGCCTAAAAGCAAGGTTC-3′ , reverse primer 5′ -GGATCTCACAG 
GCAACCACA-3′ .
Four independent experiments were carried out on separate passages of cells. Two-tailed Student’s unpaired t-test 
was used to identify statistical significance. P values of < 0.05 were taken to indicate statistical significance.
Data availability. RNA-seq data in this study has been deposited in NCBI’s Gene Expression Omnibus and 
is accessible through GEO Series accession number GSE80651.
References
1. Boute, N. et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic 
syndrome. Nat. Genet. 24, 349–354 (2000).
2. Kestilä, M. et al. Positionally cloned gene for a novel glomerular protein–nephrin–is mutated in congenital nephrotic syndrome. 
Mol. Cell 1, 575–582 (1998).
3. Hinkes, B. G. et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, 
NPHS2, WT1, and LAMB2). Pediatrics 119, e907–e919 (2007).
4. Shih, N. Y. et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science 286, 312–315 (1999).
5. Buvall, L. et al. Proteasomal degradation of Nck1 but not Nck2 regulates RhoA activation and actin dynamics. Nat. Commun. 4, 2863 
(2013).
6. Faul, C., Asanuma, K., Yanagida-Asanuma, E., Kim, K. & Mundel, P. Actin up: regulation of podocyte structure and function by 
components of the actin cytoskeleton. Trends Cell Biol. 17, 428–437 (2007).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:35671 | DOI: 10.1038/srep35671
7. Mathieson, P. W. Proteinuria and Immunity – An Overstated Relationship? N. Engl. J. Med. 359, 2492–2494 (2008).
8. Jiang, L. et al. Levamisole in steroid-sensitive nephrotic syndrome: usefulness in adult patients and laboratory insights into 
mechanisms of action via direct action on the kidney podocyte. Clin. Sci. 128, 883–893 (2015).
9. Jeruschke, S. et al. Protective Effects of the mTOR Inhibitor Everolimus on Cytoskeletal Injury in Human Podocytes Are Mediated 
by RhoA Signaling. PLoS One 8, (2013).
10. Yu, C.-C. et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 369, 2416–2423 (2013).
11. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 
14, 931–938 (2008).
12. Xing, C. et al. Direct effects of dexamethasone on human podocytes. Kidney Int. 70, 1038–1045 (2006).
13. Newton, R. Molecular mechanisms of glucocorticoid action : what is important ? Thorax 55, 603–613 (2000).
14. Niemir, Z. I. et al. Podocytes are the major source of IL-1α and IL-1β in human glomerulonephritides. Kidney Int. 52, 393–403 
(1997).
15. Sayyed, S. G. et al. Podocytes produce homeostatic chemokine stromal cell-derived factor-1/CXCL12, which contributes to 
glomerulosclerosis, podocyte loss and albuminuria in a mouse model of type 2 diabetes. Diabetologia 52, 2445–2454 (2009).
16. Ma, J. et al. TLR4 activation promotes podocyte injury and interstitial fibrosis in diabetic nephropathy. PLoS One 9, (2014).
17. Brähler, S. et al. Intrinsic proinflammatory signaling in podocytes contributes to podocyte damage and prolonged proteinuria. Am. 
J. Physiol. Renal Physiol. 303, 1473–1485 (2012).
18. Welsh, G. I. & Saleem, M. A. The podocyte cytoskeleton–key to a functioning glomerulus in health and disease. Nat Rev Nephrol 8, 
14–21 (2012).
19. Kobayashi, N., Reiser, J., Kriz, W., Kuriyama, R. & Mundel, P. Nonuniform microtubular polarity established by CHO1/MKLP1 
motor protein is necessary for process formation of podocytes. J. Cell Biol. 143, 1961–1970 (1998).
20. Kobayashi, N. et al. Molecular characterization reveals identity of microtubule-associated proteins MAP3 and MAP4. Biochem. 
Biophys. Res. Commun. 268, 306–309 (2000).
21. Kobayashi, N. Mechanism of the process formation; podocytes vs. neurons. Microsc. Res. Tech. 57, 217–223 (2002).
22. Svennilson, J., Sandberg, C. & Aperia, A. Age-dependent expression of protein phosphatase 2A in the developing rat kidney. Pediatr 
Nephrol 13, 800–805 (1999).
23. Everett, A. D., Xue, C. & Stoops, T. Developmental Expression of Protein Phosphatase 2A in the Kidney. J Am Soc Nephrol. 10, 
1737–1745 (1999).
24. Kobayashi, N. et al. Process formation of podocytes: morphogenetic activity of microtubules and regulation by protein serine/
threonine phosphatase PP2A. Histochem. Cell Biol. 115, 255–266 (2001).
25. Wasik, A. A. et al. Ezrin is down-regulated in diabetic kidney glomeruli and regulates actin reorganization and glucose uptake via 
GLUT1 in cultured podocytes. Am. J. Pathol. 184, 1727–1739 (2014).
26. Miano, J. M., Long, X. & Fujiwara, K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. 
Am. J. Physiol. Cell Physiol. 292, C70–C81 (2007).
27. Sotiropoulos, A., Gineitis, D., Copeland, J. & Treisman, R. Signal-regulated activation of serum response factor is mediated by 
changes in actin dynamics. Cell 98, 159–169 (1999).
28. Hill, C. S., Wynne, J. & Treisman, R. The Rho family GTPases RhoA, Rac1, and CDC42Hs regulate transcriptional activation by SRF. 
Cell 81, 1159–1170 (1995).
29. Wang, L. et al. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int. 81, 1075–1085 (2012).
30. Ding, W. Y. & Saleem, M. A. Current concepts of the podocyte in nephrotic syndrome. Kidney Res. Clin. Pract. 31, 87–93 (2012).
31. LIU, H. et al. α -Actinin-4 is involved in the process by which dexamethasone protects actin cytoskeleton stabilization from 
adriamycin-induced podocyte injury. Nephrology 17, 669–675 (2012).
32. Agrawal, S., Guess, A. J., Benndorf, R. & Smoyer, W. E. Comparison of Direct Action of Thiazolidinediones and Glucocorticoids on 
Renal Podocytes: Protection from Injury and Molecular Effects. Mol. Pharmacol. 80, 389–399 (2011).
33. Ransom, R. F., Lam, N. G., Hallett, M. A., Atkinson, S. J. & Smoyer, W. E. Glucocorticoids protect and enhance recovery of cultured 
murine podocytes via actin filament stabilization. Kidney Int. 68, 2473–2483 (2016).
34. Mallipattu, S. K. et al. Kruppel-Like Factor 15 Mediates Glucocorticoid-Induced Restoration of Podocyte Differentiation Markers. 
J. Am. Soc. Nephrol. 1–19, doi: 10.1681/ASN.2015060672 (2016).
35. Guo, J.-K. et al. WT1 is a key regulator of podocyte function: reduced expression levels cause crescentic glomerulonephritis and 
mesangial sclerosis. Hum. Mol. Genet. 11, 651–659 (2002).
36. Palmer, R. E. et al. WT1 regulates the expression of the major glomerular podocyte membrane protein Podocalyxin. Curr. Biol. 11, 
1805–1809 (2001).
37. Mundlos, S. et al. Nuclear localization of the protein encoded by the Wilms’ tumor gene WT1 in embryonic and adult tissues. 
Development 119, 1329 LP–1321341 (1993).
38. Kim, H.-S. et al. Identification of novel Wilms’ tumor suppressor gene target genes implicated in kidney development. J. Biol. Chem. 
282, 16278–16287 (2007).
39. Lee, S. B. et al. The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin. Cell 98, 663–673 (1999).
40. Takemoto, M. et al. Large‐scale identification of genes implicated in kidney glomerulus development and function. EMBO J. 25, 
1160–1174 (2006).
41. Motojima, M., Kume, T., Matsusaka, T. & Ichikawa, I. Foxc1 and Foxc2 cooperate in maintaining glomerular podocytes. FASEB J. 
29, 880–888 (2015).
42. White, J. T., Zhang, B., Cerqueira, D. M., Tran, U. & Wessely, O. Notch signaling, wt1 and foxc2 are key regulators of the podocyte 
gene regulatory network in Xenopus. Development 137, 1863–1873 (2010).
43. Wochnik, G. M. et al. FK506-binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation of the 
glucocorticoid receptor in mammalian cells. J. Biol. Chem. 280, 4609–4616 (2005).
44. Ayroldi, E. & Riccardi, C. Glucocorticoid-induced leucine zipper (GILZ): a new important mediator of glucocorticoid action. FASEB 
J. 23, 3649–3658 (2009).
45. Berrebi, D. et al. Synthesis of glucocorticoid-induced leucine zipper (GILZ ) by macrophages : an anti-inflammatory and 
immunosuppressive mechanism shared by glucocorticoids and IL-10. 101, 729–738 (2003).
46. Cannarile, L. et al. Increased GILZ expression in transgenic mice up-regulates Th-2 lymphokines. Blood 107, 1039–1047 (2006).
47. Soundararajan, R., Zhang, T. T., Wang, J., Vandewalle, A. & Pearce, D. A novel role for glucocorticoid-induced leucine zipper protein 
in epithelial sodium channel-mediated sodium transport. J. Biol. Chem. 280, 39970–39981 (2005).
48. Shah, S., King, E. M., Chandrasekhar, A. & Newton, R. Roles for the mitogen-Activated protein kinase (MAPK) phosphatase, 
DUSP1, in feedback control of inflammatory gene expression and repression by dexamethasone. J. Biol. Chem. 289, 13667–13679 
(2014).
49. Law, S. F. et al. Human enhancer of filamentation 1 (HEF1), a novel p130Cas-like docking protein, associates with FAK, and induces 
pseudohyphal growth in yeast. Mol Cell Biol 16, 3327–3337 (1996).
50. Zhong, J. et al. NEDD9 stabilizes focal adhesions, increases binding to the extra-cellular matrix and differentially effects 2D versus 
3D cell migration. PLoS One 7, (2012).
51. Hughes, C. A. & Bennett, V. Adducin: A physical model with implications for function in assembly of spectrin-actin complexes. 
Journal of Biological Chemistry 270, 18990–18996 (1995).
www.nature.com/scientificreports/
1 1Scientific RepoRts | 6:35671 | DOI: 10.1038/srep35671
52. Gardner, K. & Bennett, V. Modulation of spectrin-actin assembly by erythrocyte adducin. Nature 328, 359–362 (1987).
53. Abdi, K. M. & Bennett, V. Adducin Promotes Micrometer-Scale Organization of β 2-Spectrin in Lateral Membranes of Bronchial 
Epithelial Cells. Mol. Biol. Cell 19, 536–545 (2008).
54. Naydenov, N. G. & Ivanov, A. I. Adducins Regulate Remodeling of Apical Junctions in Human Epithelial Cells. Mol. Biol. Cell 21, 
3506–3517 (2010).
55. Chan, P. C., Hsu, R. Y. C., Liu, C. W., Lai, C. C. & Chen, H. C. Adducin-1 is essential for mitotic spindle assembly through its 
interaction with myosin-X. J. Cell Biol. 204, 19–28 (2014).
56. Sengupta, S., Vonesch, J. L., Waltzinger, C., Zheng, H. & Wasylyk, B. Negative cross-talk between p53 and the glucocorticoid receptor 
and its role in neuroblastoma cells. EMBO J. 19, 6051–6064 (2000).
57. Schoenwaelder, S. M. & Burridge, K. Bidirectional signalling between the cytoskeleton and integrins. Curr.Opp.Cell Biol. 11, 
274–286 (1999).
58. Bill, H. M. et al. Epidermal Growth Factor Receptor-Dependent Regulation of Integrin-Mediated Signaling and Cell Cycle Entry in 
Epithelial Cells. Mol Cell Biol 24, 8586–8599 (2004).
59. Lennon, R., Randles, M. J. & Humphries, M. J. The importance of podocyte adhesion for a healthy glomerulus. Front. Endocrinol. 
(Lausanne). 5, 160 (2014).
60. Hudson, B. G., Tryggvason, K., Sundaramoorthy, M. & Neilson, E. G. Alport’s syndrome, Goodpasture’s syndrome, and type IV 
collagen. N. Engl. J. Med. 348, 2543–2556 (2003).
61. Hudson, B. G., Reeders, S. T. & Tryggvason, K. Type IV collagen: Structure, gene organization, and role in human diseases. 
Molecular basis of goodpasture and alport syndromes and diffuse leiomyomatosis. J. Biol. Chem. 268, 26033–26036 (1993).
62. Greka, A. & Mundel, P. Regulation of podocyte actin dynamics by calium. Semin. Nephrol. 32, 319–326 (2012).
63. Clapham, D. E. Calcium Signaling. Cell 131, 1047–1058 (2007).
64. Saleem, M. A. et al. A Conditionally Immortalized Human Podocyte Cell Line Demonstrating Nephrin and Podocin Expression. 
J Am Soc Nephrol. 630–638 (2002).
65. Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105–1111 (2009).
66. Anders, S., Pyl, P. T. & Huber, W. HTSeq-A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 
166–169 (2015).
67. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
68. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for differential expression analysis of digital gene 
expression data. Bioinformatics 26, 139–140 (2009).
69. Hardcastle, T. J. & Kelly, K. A. baySeq: empirical Bayesian methods for identifying differential expression in sequence count data. 
BMC Bioinformatics 11, 422 (2010).
70. Rapaport, F. et al. Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data. Genome Biol 14, 
R95 (2013).
71. Fang, H. & Gough, J. SupraHex: An R/Bioconductor package for tabular omics data analysis using a supra-hexagonal map. Biochem. 
Biophys. Res. Commun. 443, 285–289 (2014).
72. Fang, H. & Gough, J. The ‘dnet’ approach promotes emerging research on cancer patient survival. Genome Med. 6, 1–15 (2014).
73. Szklarczyk, D. et al. STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, 
D447–D452 (2015).
Acknowledgements
This work was funded by a grant from Kids Kidney Research to G.I.W. and P.W.M., L.J. is fully sponsored by a 
University of Bristol PhD Scholarship. M.R. and RNA-seq computing resources were supported by an EPSRC 
grant EP/K008250/1. C.C.T.H. was funded by the High Impact Research Chancellory Grant (UM.C/625/1/HIR/
MOHE/MED/22 H-20001-E000086) from the University of Malaya, Malaysia.
Author Contributions
L.J., P.W.M. and G.I.W. designed the study. L.J., C.C.T.H., M.R., C.W., J.C. and G.I.W. conducted the experiments. 
L.J., C.C.T.H., M.R., C.C. and G.I.W. performed data analysis. L.J., P.W.M. and G.I.W. wrote the manuscript.
Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Jiang, L. et al. RNA sequencing analysis of human podocytes reveals glucocorticoid 
regulated gene networks targeting non-immune pathways. Sci. Rep. 6, 35671; doi: 10.1038/srep35671 (2016).
This work is licensed under a Creative Commons Attribution 4.0 International License. The images 
or other third party material in this article are included in the article’s Creative Commons license, 
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, 
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this 
license, visit http://creativecommons.org/licenses/by/4.0/
 
© The Author(s) 2016
